Tumour Hypoxia And Radiation Therapy

Learn more about tumour hypoxia and radiation therapy

When a tumour is diagnosed, the usual route is to begin radiation therapy and chemotherapy. As we know, this can cause a great deal of stress for the patient, as well as complications and increased pain.

Whilst this has been proven countless times to work, what we have discovered is that with tumours, there is no way to measure the level of hypoxia. What we have found through our extensive research is that low levels (also known as hypoxia) are often associated with resistance to treatments.

At ManTRa Diagnostics we have developed tumour-site specific gene expression signatures to assess hypoxia. With our technology we can deliver major advances in personalised cancer medicine, with the goal to allow patients to make more informed choices.

Who are we? 

We are a diagnostics Development Company that originates from the Department of Translational Radiobiology based within the Manchester Cancer Research Centre.

On our blog we explain more about our findings, and our recent blog post is about re-thinking commercialisation. We also encourage you to learn more about us and meet our team.

For those that are interested in discussing our technology and how we can work with you, please register your interest via our contact form.